Eli Lilly and Company (NYSE:LLY) Shares Bought by Gotham Asset Management LLC
Gotham Asset Management LLC raised its stake in Eli Lilly and Company (NYSE:LLY) by 1,071.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 448,591 shares of the company’s stock after buying an additional 410,286 shares during the period. Gotham Asset Management LLC’s holdings in Eli Lilly and were worth $37,731,000 as of its most recent filing with the SEC.
Other large investors have also made changes to their positions in the company. First Command Financial Services Inc. increased its stake in shares of Eli Lilly and by 7.3% in the first quarter. First Command Financial Services Inc. now owns 1,227 shares of the company’s stock valued at $103,000 after buying an additional 84 shares in the last quarter. Heritage Trust Co acquired a new stake in shares of Eli Lilly and during the first quarter valued at about $135,000. Penserra Capital Management LLC increased its stake in shares of Eli Lilly and by 9.5% in the first quarter. Penserra Capital Management LLC now owns 2,024 shares of the company’s stock valued at $170,000 after buying an additional 176 shares in the last quarter. Crestwood Advisors Group LLC acquired a new stake in shares of Eli Lilly and during the first quarter valued at about $179,000. Finally, Sandy Spring Bank increased its stake in shares of Eli Lilly and by 51.8% in the first quarter. Sandy Spring Bank now owns 2,198 shares of the company’s stock valued at $185,000 after buying an additional 750 shares in the last quarter. 75.61% of the stock is owned by hedge funds and other institutional investors.
Eli Lilly and Company (NYSE:LLY) traded down 0.47% during mid-day trading on Friday, reaching $81.15. The company’s stock had a trading volume of 2,446,392 shares. The company has a 50 day moving average of $82.91 and a 200-day moving average of $81.72. Eli Lilly and Company has a 52-week low of $64.18 and a 52-week high of $86.72. The stock has a market cap of $85.61 billion, a PE ratio of 35.11 and a beta of 0.34.
Eli Lilly and (NYSE:LLY) last announced its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 earnings per share for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. The firm had revenue of $5.82 billion for the quarter, compared to the consensus estimate of $5.60 billion. Eli Lilly and had a return on equity of 28.71% and a net margin of 11.12%. The business’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.86 earnings per share. Equities analysts forecast that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be given a dividend of $0.52 per share. This represents a $2.08 dividend on an annualized basis and a yield of 2.56%. The ex-dividend date of this dividend is Friday, August 11th. Eli Lilly and’s dividend payout ratio (DPR) is presently 90.04%.
Several brokerages recently issued reports on LLY. BidaskClub raised Eli Lilly and from a “sell” rating to a “hold” rating in a research note on Wednesday, June 14th. Barclays PLC increased their price objective on Eli Lilly and from $85.00 to $90.00 and gave the stock an “overweight” rating in a research note on Tuesday, July 4th. BMO Capital Markets reaffirmed a “sell” rating and issued a $73.00 target price on shares of Eli Lilly and in a research report on Friday, August 4th. Berenberg Bank reaffirmed a “buy” rating and issued a $100.00 target price on shares of Eli Lilly and in a research report on Thursday, July 27th. Finally, Jefferies Group LLC reaffirmed a “buy” rating and issued a $96.00 target price (up from $93.00) on shares of Eli Lilly and in a research report on Thursday, July 13th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and twelve have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $88.27.
In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 215,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 20th. The stock was sold at an average price of $83.05, for a total transaction of $17,855,750.00. Following the transaction, the insider now owns 124,475,804 shares of the company’s stock, valued at $10,337,715,522.20. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Michael J. Harrington sold 22,833 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The stock was sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now directly owns 62,056 shares in the company, valued at approximately $4,962,618.32. The disclosure for this sale can be found here. In the last three months, insiders have sold 669,733 shares of company stock worth $55,845,287. Company insiders own 0.20% of the company’s stock.
Eli Lilly and Company Profile
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY).
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.